Skip to main content
European Commission logo print header

App on AR-Smartglasses for improved autonomy and mobility of visual impaired persons

Periodic Reporting for period 1 - Retiplus (App on AR-Smartglasses for improved autonomy and mobility of visual impaired persons)

Berichtszeitraum: 2018-02-01 bis 2018-06-30

Low Vision (LV) is a disabling condition caused by eye diseases that substantially decrease the ability to see causing problems not fixable by usual means (glasses, contact lenses, medicines or surgery).
LV deteriorates the quality of life (QOL) of affected people (246 million), who lose their autonomy and mobility. Besides altering the life of the patient, it also has a huge impact on healthcare systems. According to AMD Alliance International, by 2020 the direct costs of vision loss worldwide will reach €2.8 trillion and €760 billion for indirect costs.
Our patented technology is an App for wearable augmented reality Smartglasses (SGs) that will improve LV people vision in all-day situations. Our solution is a disruptive evolution with respect to conventional aids for LV people offering a versatile, discrete, and cost affordable solution for improved QOL.
Performing a market analysis and preparing a consistent go-to-market plan.
Defining a technological roadmap for RETIPLUS evolution and migration to other SGs.
Defining a plan for financial readiness.
COMMERCIAL FEASIBILITY STUDY: A detailed market analysis (value, forecast, segments, drivers, etc.) performed during Retiplus FS allowed us validating our market hypothesis and the market opportunity for our technology. We also defined the best go-to-market plan considering the features of our potential clients and stakeholders.
TECHNICAL FEASIBILITY STUDY: We defined a 2-year work plan and methodology, including a technological roadmap for RETIPLUS evolution and adaptation based on customer and professionals´ feedbacks to achieve full technological readiness.
FINANCIAL FEASIBILITY STUDY: FS has also allowed us analyzing the funding requirements to bring Retiplus System to the market. We also explored different funding sources (public funding, bank loans, private equity, etc.) to achieve these goals.
Retiplus System is a single device solution whose features widely overpass current LV aids, allowing a notable improvement on QOL of LV people and reducing the economic impact on healthcare systems as well as other indirect costs (lost productivity, etc.).